Published in Urology on February 16, 2010
Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate (2010) 2.40
Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med (2010) 0.99
Referrals among cancer services organizations serving underserved cancer patients in an urban area. Am J Public Health (2011) 0.83
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. J Oncol Pract (2011) 0.78
Current opinion on the role of testosterone in the development of prostate cancer: a dynamic model. BMC Cancer (2015) 0.75
Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer. Am J Mens Health (2015) 0.75
Editorial comment. Urology (2010) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
The impact of socioeconomic status on survival after cancer in the United States : findings from the National Program of Cancer Registries Patterns of Care Study. Cancer (2008) 3.13
Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer (2008) 2.60
Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst (2003) 2.52
Racial differences in screening for prostate cancer in the elderly. Arch Intern Med (2004) 2.34
Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol (2007) 2.09
Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care (1998) 1.88
Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States). Cancer Causes Control (2006) 1.38
Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer. Med Care (2004) 1.31
Factors contributing to the racial differences in prostate cancer mortality. BJU Int (2005) 1.26
Decrease in racial disparities in the staging evaluation for prostate cancer after publication of staging guidelines. J Urol (2007) 1.24
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy (2012) 2.49
Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.25
Local protease signaling contributes to neural tube closure in the mouse embryo. Dev Cell (2010) 2.19
Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer. J Clin Oncol (2012) 2.15
A universal telomerase RNA core structure includes structured motifs required for binding the telomerase reverse transcriptase protein. Proc Natl Acad Sci U S A (2004) 1.83
Burden associated with chronic sleep maintenance insomnia characterized by nighttime awakenings among women with menopausal symptoms. Menopause (2010) 1.52
Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A (2006) 1.50
Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. Urology (2011) 1.44
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. Am J Manag Care (2011) 1.39
Genome of multidrug-resistant uropathogenic Escherichia coli strain NA114 from India. J Bacteriol (2011) 1.33
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
The cost of poor sleep: workplace productivity loss and associated costs. J Occup Environ Med (2010) 1.20
A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol (2013) 1.16
Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. J Am Geriatr Soc (2009) 1.11
A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res (2004) 1.08
Virulence characteristics and genetic affinities of multiple drug resistant uropathogenic Escherichia coli from a semi urban locality in India. PLoS One (2011) 1.08
Cataract blindness in Chakwal District, Pakistan: results of a survey. Ophthalmic Epidemiol (2003) 1.07
A differential role for nitric oxide in two forms of physiological angiogenesis in mouse. J Physiol (2005) 1.07
Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res (2006) 1.05
Eligibility and take-up of the Medicare Part D low-income subsidy. Inquiry (2012) 1.02
Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J Thorac Oncol (2011) 0.99
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health (2009) 0.98
Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene (2002) 0.98
Adherence to inhaled corticosteroid use and local adverse events in persistent asthma. Am J Manag Care (2008) 0.97
Do we still need the surgeon to close the persistently patent arterial duct? Cardiol Young (2006) 0.97
Testicular germ cell tumors: biology and clinical update. Curr Opin Oncol (2012) 0.94
Testicular germ cell tumors: biology and clinical update. Curr Opin Oncol (2013) 0.93
Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare. Med Care (2015) 0.93
Androgen deprivation and stem cell markers in prostate cancers. Int J Clin Exp Pathol (2009) 0.93
The efficacy and safety of the Amplatzer ductal occluder in young children and infants. Cardiol Young (2005) 0.92
GSTP1 methylation and polymorphism increase the risk of breast cancer and the effects of diet and lifestyle in breast cancer patients. Exp Ther Med (2012) 0.92
Engaging hard-to-reach patients in patient-centered outcomes research. J Comp Eff Res (2013) 0.91
Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US. Pharmacoeconomics (2010) 0.91
Chemotherapy treatment and survival in older women with estrogen receptor-negative metastatic breast cancer: a population-based analysis. J Am Geriatr Soc (2011) 0.91
Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr Opin Oncol (2014) 0.90
Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy. Clin Cancer Res (2008) 0.89
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol (2013) 0.88
A wide spectrum of dengue IgM and PCR positivity post-onset of illness found in a large dengue 3 outbreak in Pakistan. J Med Virol (2008) 0.87
Update on testicular germ cell tumors. Curr Opin Oncol (2010) 0.87
A sustainable strategy to prevent misuse of antibiotics for acute respiratory infections. PLoS One (2012) 0.87
Specificity of ligand binding to transport sites: Ca2+ binding to the Ca2+ transport ATPase and its dependence on H+ and Mg2+. Arch Biochem Biophys (2008) 0.87
Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer. BMC Med Res Methodol (2014) 0.86
(-)-Epigallocatechin-3-gallate induces apoptosis and inhibits invasion and migration of human cervical cancer cells. Asian Pac J Cancer Prev (2012) 0.86
Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells. Mol Pharmacol (2012) 0.85
Alpha(2)-blocker helps to avoid systemic to pulmonary shunt in a prostaglandin dependent infant with critical pulmonary valve stenosis. J Coll Physicians Surg Pak (2006) 0.85
Insomnia-related comorbidities and economic costs among a commercially insured population in the United States. Curr Med Res Opin (2009) 0.85
Hospital center effect for laparoscopic colectomy among elderly stage I-III colon cancer patients. Ann Surg (2014) 0.84
The potential impact of comparative effectiveness research on the health of minority populations. Health Aff (Millwood) (2010) 0.84
Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol (2008) 0.83
Frequency of extended spectrum beta lactamase producing enterobacteriaceae among urinary pathogen isolates. J Coll Physicians Surg Pak (2011) 0.82
Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome. Appl Health Econ Health Policy (2012) 0.82
Bacteremia due to Aeromonas hydrophila in acute lymphoblastic leukemia. J Coll Physicians Surg Pak (2013) 0.82
The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice. Prostate (2009) 0.82
Sensitivity analysis in cost-effectiveness studies: from guidelines to practice. Pharmacoeconomics (2011) 0.82
Bovine valved xenograft conduits in the extracardiac Fontan procedure. J Thorac Cardiovasc Surg (2003) 0.81
Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in locally advanced breast cancers in Indian women. Hum Pathol (2008) 0.81
Pleural empyema due to Salmonella typhi. J Coll Physicians Surg Pak (2012) 0.81
Regulators of prostate cancer stem cells. Curr Opin Oncol (2014) 0.81
Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells. Arch Biochem Biophys (2007) 0.81
Recent developments in germ cell tumors of the testes. Curr Opin Oncol (2008) 0.80
Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization. Postgrad Med (2013) 0.80
Anti-carcinogenic effects of sulforaphane in association with its apoptosis-inducing and anti-inflammatory properties in human cervical cancer cells. Cancer Epidemiol (2010) 0.80
Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients. Am J Health Syst Pharm (2010) 0.80
Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare. Pharmacoeconomics (2014) 0.80
Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother (2008) 0.79
Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients. Cancer Med (2013) 0.79
Discriminatory power of a 25-item distress screening tool: a cross-sectional survey of 251 cancer survivors. Qual Life Res (2014) 0.79
Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. Cancer Med (2014) 0.78
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. J Oncol Pract (2011) 0.78
Evolving role of surgery, radiation, hormone therapy, and chemotherapy in high-risk locally advanced prostate cancer. Clin Genitourin Cancer (2006) 0.78
A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer. J Med Econ (2011) 0.78
Multispecialist Care and Mortality in Hepatocellular Carcinoma. Am J Clin Oncol (2015) 0.78
Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.78
Improving confidence in observational studies : should statistical analysis plans be made publicly available? Pharmacoeconomics (2013) 0.77
Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care (2010) 0.77
Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. Value Health (2013) 0.77
Testicular germ cell tumors. Curr Opin Oncol (2007) 0.77
Acute pulmonary thromboembolism during mitral valve repair. Heart Lung Circ (2007) 0.77
Economic analysis of triptan therapy for acute migraine: a Medicaid perspective. Pharmacotherapy (2007) 0.77
G894T and 4a/b polymorphisms of NOS3 gene are not associated with cancer risk: a meta-analysis. Asian Pac J Cancer Prev (2015) 0.77
Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States. J Occup Environ Med (2010) 0.77
Update on testicular germ cell tumors. Curr Opin Oncol (2011) 0.77
Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1. Biochim Biophys Acta (2013) 0.77
Metabolic targets for potential prostate cancer therapeutics. Curr Opin Oncol (2016) 0.77
Stent implantation to maintain patency of a stenosed Blalock Taussig shunt. Asian Cardiovasc Thorac Ann (2005) 0.77
Implications of ubiquitin ligases in castration-resistant prostate cancer. Curr Opin Oncol (2015) 0.76
Specific 50'CpG island methylation signatures of FHIT and p16 genes and their potential diagnostic relevance in Indian breast cancer patients. DNA Cell Biol (2008) 0.76
Thapsigargin resistance in human prostate cancer cells. Cancer (2006) 0.76